Biolidics Ltd. (SG:8YY)
SGX:8YY
Want to see SG:8YY full AI Analyst Report?
8YY Stock Chart & Stats
S$0.04
<S$0.01(3.70%)
At close: 4:00 PM EST
S$0.04
<S$0.01(3.70%)
Day’s Range― - ―
52-Week RangeS$0.02 - S$0.09
Previous CloseN/A
Volume13.75M
Average Volume (3M)412.95K
Market Cap
S$78.00M
Enterprise ValueS$91.99M
Total Cash (Recent Filing)S$557.00K
Total Debt (Recent Filing)S$2.41M
Price to Earnings (P/E)―
Beta0.90
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,733,441,800
10 Day Avg. Volume410,990
30 Day Avg. Volume412,950
Financial Highlights & Ratios
PEG Ratio0.66
Price to Book (P/B)58.30
Price to Sales (P/S)16.93
P/FCF Ratio-247.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue ReboundA ~197% revenue rebound to ~5.3m in 2025 suggests meaningful commercialization progress and improved market traction. Sustained revenue growth can enable better fixed-cost absorption, support margin expansion and provide a platform for recurring consumables revenue to scale over months to years.
Recurring Consumables ModelA consumables-driven model creates durable, repeatable revenue tied to installed devices and ongoing testing. This business structure fosters customer stickiness and predictable per-test revenue, supporting long-term margin sustainability and lifecycle monetization as installed base grows.
Improving Cash Flow TrendMaterial improvement in operating/free cash flow from ~-2.3m to ~-0.36m indicates operational progress and that revenue gains are beginning to translate into better cash performance. If sustained, this trend reduces financing reliance and supports a path toward self-funded growth over several quarters.
Bears Say
Persistent LossesRecurring, sizable net losses (≈4.0m in 2025) show the company has not yet achieved operational leverage or sustainable profitability. Continued losses can erode capital, necessitate dilutive funding, and limit reinvestment, posing a structural barrier until scale or margins materially improve.
Thin Equity / LeverageA modest equity base (~1.5m) alongside meaningful debt (~2.4m) and a prior history of negative equity indicate limited balance-sheet flexibility. This elevates refinancing and solvency risk, constrains strategic options and increases the likelihood of external capital needs if operational shocks occur.
Negative Cash GenerationSustained negative operating and free cash flow forces ongoing dependence on external funding or asset drawdowns. Even with improvement, persistent cash outflows limit the company's ability to self-fund growth, heighten dilution risk, and restrict investments necessary to scale diagnostics operations.
Biolidics Ltd. News
8YY FAQ
What was Biolidics Ltd.’s price range in the past 12 months?
Biolidics Ltd. lowest share price was S$0.02 and its highest was S$0.09 in the past 12 months.
What is Biolidics Ltd.’s market cap?
Biolidics Ltd.’s market cap is S$78.00M.
When is Biolidics Ltd.’s upcoming earnings report date?
Biolidics Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 55 days.
How were Biolidics Ltd.’s earnings last quarter?
Currently, no data Available
Is Biolidics Ltd. overvalued?
According to Wall Street analysts Biolidics Ltd.’s price is currently Overvalued.
Does Biolidics Ltd. pay dividends?
Biolidics Ltd. does not currently pay dividends.
What is Biolidics Ltd.’s EPS estimate?
Biolidics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biolidics Ltd. have?
Biolidics Ltd. has 1,733,441,800 shares outstanding.
What happened to Biolidics Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Biolidics Ltd.?
Currently, no hedge funds are holding shares in SG:8YY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biolidics Ltd. Stock Smart Score
Company Description
Biolidics Ltd.
Embracing Future Holdings Limited, a Singapore-based medical technology firm, specializes in precision medicine, focusing on developing diagnostic solutions. Operating across Japan, Hong Kong, Thailand, Malaysia, and the United States, its business is structured into Cancer, Infectious Diseases, and Laboratory Services segments. The company's key innovations include the ClearCell FX1 System, an automated device that, using Streck Cell-free DNA BCT and EDTA tubes, isolates intact and viable circulating tumor cells (CTCs) from small blood samples. It also provides the CTChip FR1 biochip for separating CTCs from leukocytes, alongside offering general laboratory services. Established in 2009, the company was formerly known as Biolidics Limited, adopting its current name in June 2025.
Technical Analysis
Cordlife Group
―
ISEC Healthcare Ltd
―
Medtecs International Corporation Ltd.
―
AJJ Medtech Holdings Limited
―
Singapore Institute of Advanced Medicine Holdings Ltd.
―
Options Prices
Currently, No data available
---